Cosmos Health Inc. has expanded its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania, projecting annualized orders to exceed 54,000 units. The expansion builds on the partnership the companies launched in April 2025, reflecting strong market reception. Average monthly orders have already exceeded 4,500 units, driven by recommendations from doctors and healthcare professionals across the country.

The products are distributed throughout Albania, supporting broad consumer access. Pharma Cell, based in Tirana, is a fast-growing pharmaceutical company specializing in high-quality food supplements. It operates an established distribution network serving pharmacies and healthcare professionals in the region.

Partnership Details

The expanded relationship underscores the momentum of Sky Premium Life's global growth. The following table outlines the key metrics associated with the partnership expansion:

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated that the growth of the partnership reflects the strong momentum of Sky Premium Life in Albania. He noted that products are reaching a broad population, backed by recommendations from healthcare professionals. The company aims to continue growing the brand's presence in the market alongside Pharma Cell.

Cosmos Health Inc. has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million. This capital allocation strategy underscores the company's belief that its shares remain undervalued relative to the strength and potential of its business.

Greg Siokas, CEO of Cosmos Health, stated that reaching over five million shares repurchased highlights the company's continued commitment to the program. The company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the company’s sole discretion. The program allows for acquisitions through open market purchases, privately negotiated transactions, or other permitted means, in accordance with SEC Rules 10b5-1 and 10b-18.

Share Repurchase Program Details

Cosmos Health Inc., incorporated in 2009 in Nevada, operates as a diversified, vertically integrated global healthcare group. The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, and bio-bebe. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.